TriangleTalquetamab (NCT04634552)
Talquetamab trial for Hematological Malignancies (NCT04634552). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory multiple myeloma. Most groups require at least three prior treatment lines; another requires exposure to a proteasome inhibitor, an immune-modulating drug and an anti-CD38 antibody.
The idea: give talquetamab injections, linking T cells to GPRC5D on myeloma cells to trigger immune attack. Some groups permit earlier T-cell-directed therapy; others exclude it. Certain groups receive tocilizumab to prevent cytokine-release syndrome. Researchers measure responses and safety at previously selected doses.
This phase 2 study plans 510 patients. Janssen sponsors nine recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.